(Reuters) - Braeburn Pharmaceuticals Inc, the maker of the first long-acting implant to treat opioid addiction in the United States, said on Thursday that it had decided not to proceed with its initial public offering, citing current market environment. (Source: Reuters: Health)
from MedWorm: AddictionNews https://medworm.com/index.php?rid=292794750&cid=d_2_26_f&fid=23271&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2Freuters%2FhealthNews%2F%7E3%2FEmsGojvnDAE%2Fus-braeburn-pharms-ipo-idUSKBN15H1TU
No comments:
Post a Comment